INTEGRATED BIOPHARMA director granted 50,000 options
INTEGRATED BIOPHARMA director Robert Canarick received a grant of 50,000 stock options for common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
INTEGRATED BIOPHARMA director Robert Canarick received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options between September 2026 and June 2027.
Insider Trade Summary
Grant/Award: 50,000 shares
Grant/Award
1 txn
Insider
Canarick Robert
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,000 contracts (Direct)
Footnotes (1)
- F1. The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.
Key Figures
Option grant size: 50,000 options
Exercise price: $0.19 per share
Options after grant: 50,000 options
+2 more
5 metrics
Option grant size
50,000 options
Stock Option (Right to Buy) grant to director
Exercise price
$0.19 per share
Conversion or exercise price of options
Options after grant
50,000 options
Total derivative securities following transaction
Vesting installment size
12,500 options
Each of four vesting dates from 2026 to 2027
Option expiration date
June 24, 2036
Expiration of stock option grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date
4 terms
Stock Option (Right to Buy) financial
"Security title is described as "Stock Option (Right to Buy)"."
exercise price financial
"Conversion or exercise price is reported as $0.1900 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock options vest and become exercisable in four equal installments."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The options carry an expiration date of June 24, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did INBP director Robert Canarick report on this Form 4?
Robert Canarick reported receiving a grant of 50,000 stock options for INTEGRATED BIOPHARMA common stock. These options were awarded as compensation, not purchased on the open market, and represent a new derivative position tied to future potential share ownership.
What is the exercise price of Robert Canarick’s INBP stock options?
The granted stock options have an exercise price of $0.19 per share. This is the fixed price at which Canarick can buy INTEGRATED BIOPHARMA common stock if he chooses to exercise the options before expiration.
When do Robert Canarick’s 50,000 INBP stock options vest?
The 50,000 stock options vest in four equal installments of 12,500 options each. Vesting dates are September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning the award with multi-year service to the company.
When do the newly granted INBP stock options held by Robert Canarick expire?
The stock options granted to Robert Canarick expire on June 24, 2036. After that expiration date, any unexercised options will lapse, and he will no longer have the right to buy INTEGRATED BIOPHARMA shares at the $0.19 exercise price.
How many INBP options does Robert Canarick hold after this Form 4 transaction?
Following this grant, Robert Canarick holds 50,000 stock options according to the filing. These options are subject to the disclosed vesting schedule and provide potential future rights to acquire INTEGRATED BIOPHARMA common stock at $0.19 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
